Abstract
Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have